Kiromic BioPharma, Inc. (KRBP)

USD 1.1

(14.58%)

Market Cap (In USD)

1.7 Million

Revenue (In USD)

-

Net Income (In USD)

-21.29 Million

Avg. Volume

2449.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.275-3.78
PE
-
EPS
-
Beta Value
1.979
ISIN
US4976342042
CUSIP
497634105
CIK
1792581
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Pietro Bersani CPA, J.D.
Employee Count
-
Website
https://www.kiromic.com
Ipo Date
2020-10-16
Details
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.